Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy

Yokokawa Takashi; Suzuki Kenichi; Sugisaki Takahito; Kobayashi Kazuo; Shouji Daigo; Watanabe Hiroshi; Kawakami Kazuyoshi; Takiguchi Tomomi; Aoyama Takeshi; Kobayashi Kokoro; Takahashi Shunji; Ito Yoshinori; Ohno Shinji; Hama Toshihiro

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy

【24h】

Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy

机译：原发性PEGFILGRASTIM预防对新辅助/佐剂FEC-100化疗中相对剂量强度的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background/Aim: This study aimed was to clarify the impact of pegfilgrastim (PEG) 3.6 mg primary prophylaxis of febrile neutropenia (FN) on the average relative dose intensity (ARDI) of neoadjuvant/adjuvant FEC-100 for breast cancer. Materials and Methods: This retrospective, single-centre cohort study including 296 patients who received FEC-100 compared PEG and non-PEG groups. The PEG group received PEG 3.6 mg as a single subcutaneous injection in each study cycle. The primary endpoint was the ARDI of FEC-100. The secondary endpoints were patient percentage of ARDI=85%, factors associated with ARDI=85%, and reasons for reduced ARDI. Results: The PEG group showed significantly higher mean ARDI (95.6% versus 90.7%, p<0.001) and patient percentage of ARDI=85% (93.0% versus 79.9%, p=0.001). PEG was significantly associated with ARDI=85% (p=0.009). Neutropenia and FN, the main reasons for reduced ARDI, were significantly lower in the PEG group (p<0.05). Conclusion: Primary PEG 3.6 mg prophylaxis increased the ARDI of FEC-100.

机译：背景/目的：本研究旨在阐明PEGFILGRASTIM（PEG）3.6mg初级预防的PEGFILGRASTIM（PEG）3.6mg初前预防对Neoadjuvant /佐剂FEC-100的平均相对剂量强度（ARDI）进行乳腺癌。材料和方法：这种回顾性，单中心队列研究，包括296名接受FEC-100比较PEG和非PEG组的患者。 PEG组在每种研究循环中接受PEG 3.6mg作为单一皮下注射。主要终点是FEC-100的ARDI。次要终点是ARDI = 85％的患者百分比，与ARDI相关的因子= 85％，以及降低ARDI的原因。结果：PEG组显示出明显高的平均值（95.6％，对90.7％，P <0.001）和患者的ARDI = 85％（93.0％，对79.9％，P = 0.001）。 PEG显着与ARDI = 85％（p = 0.009）。中性粒细胞症和FN，降低ARDI的主要原因在PEG组中显着较低（P <0.05）。结论：初级PEG 3.6毫克预防促进FEC-100的ardi。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2020年第2期|共7页
作者
Yokokawa Takashi; Suzuki Kenichi; Sugisaki Takahito; Kobayashi Kazuo; Shouji Daigo; Watanabe Hiroshi; Kawakami Kazuyoshi; Takiguchi Tomomi; Aoyama Takeshi; Kobayashi Kokoro; Takahashi Shunji; Ito Yoshinori; Ohno Shinji; Hama Toshihiro;
展开▼
作者单位

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Hoshi Univ Div Appl Pharmaceut Educ &

Res Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Breast Oncol Ctr Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Med Oncol Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Breast Oncol Ctr Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Breast Oncol Ctr Tokyo Japan;

Japanese Fdn Canc Res Canc Inst Hosp Dept Pharm Tokyo Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Pegfilgrastim; relative dose intensity; febrile neutropenia; breast cancer; FEC-100;

机译：Pegfilgrastim;相对剂量强度;发热中性粒细胞率;乳腺癌;FEC-100;

相似文献

外文文献
中文文献
专利

1. Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy [J] . Yokokawa Takashi, Suzuki Kenichi, Sugisaki Takahito, Anticancer Research: International Journal of Cancer Research and Treatment . 2020,第2期

机译：原发性PEGFILGRASTIM预防对新辅助/佐剂FEC-100化疗中相对剂量强度的影响
2. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33) [J] . Sibylle Loibl, Volkmar Mueller, Gunter von Minckwitz, Supportive Care in Cancer . 2011,第11期

机译：在前瞻性，多中心GAIN研究中，第2天与第4天使用pegfilgrastim比较主要预防淋巴结阳性原发性乳腺癌患者进行强剂量密集化疗的情况：（GBG 33）
3. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). [J] . Loibl S, Mueller V, von Minckwitz G, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2011,第11期

机译：在前瞻性，多中心GAIN研究中比较第2天与第4天使用pegfilgrastim预防强阳性剂量密集化疗的淋巴结阳性原发性乳腺癌患者的比较：（GBG 33）。
4. Correlation based Feature Selection impact on the classification of breast cancer patients response to neoadjuvant chemotherapy [C] . S. Rosati, C. M. Gianfreda, G. Balestra, International Symposium on Medical Measurements and Applications . 2018

机译：基于相关特征选择对乳腺癌患者新辅助化疗反应分类的影响
5. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
6. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity [O] . Norimitsu Yabusaki, Tsutomu Fujii, Suguru Yamada, -1

机译：相对剂量强度在胰腺导管腺癌辅助化疗中的意义-包括影响相对剂量强度的临床病理因素分析
7. Impact of relative dose intensity of FOLFOX adjuvant chemotherapy on risk of death among stage III colon cancer patients [O] . Meijiao Zhou, Trevor D. Thompson, Hui-Yi Lin, 2020

机译：Folfox辅助化疗相对剂量强度对III阶段结肠癌患者死亡风险的影响

Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅